{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:58:48Z","timestamp":1783357128458,"version":"3.54.6"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13271-w","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:41:48Z","timestamp":1733395308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["NTRK fusion promotes tumor migration and invasion through epithelial\u2013mesenchymal transition and closely interacts with ECM1 and NOVA1"],"prefix":"10.1186","volume":"24","author":[{"given":"Siqing","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"13271_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","volume":"72","author":"EJ Huang","year":"2003","unstructured":"Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609\u201342.","journal-title":"Annu Rev Biochem"},{"key":"13271_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731\u201347.","journal-title":"Nat Rev Clin Oncol"},{"key":"13271_CR3","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-10-3034","volume":"17","author":"T Harada","year":"2011","unstructured":"Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, Giaccone G. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011;17:2638\u201345.","journal-title":"Clin Cancer Res"},{"key":"13271_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/humu.20707","volume":"29","author":"A Marchetti","year":"2008","unstructured":"Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, Malatesta S, Chella A, Barassi F, Mucilli F, Camplese P, D\u2019Antuono T, Sacco R, Buttitta F. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat. 2008;29:609\u201316.","journal-title":"Hum Mutat"},{"key":"13271_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2217\/14796694.1.5.689","volume":"1","author":"A Tacconelli","year":"2005","unstructured":"Tacconelli A, Farina AR, Cappabianca L, Gulino A, Mackay AR. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. Future Oncol. 2005;1:689\u201398.","journal-title":"Future Oncol"},{"key":"13271_CR6","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1128\/MCB.20.23.8655-8666.2000","volume":"20","author":"GW Reuther","year":"2000","unstructured":"Reuther GW, Lambert QT, Caligiuri MA, Der CJ. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol Cell Biol. 2000;20:8655\u201366.","journal-title":"Mol Cell Biol"},{"key":"13271_CR7","doi-asserted-by":"publisher","first-page":"e144847","DOI":"10.1172\/JCI144847","volume":"131","author":"YA Lee","year":"2021","unstructured":"Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, Won JK, Jung KC, Kwon D, Chung EJ, Hah JH, Paeng JC, Kim JH, Choi J, Kim OH, Oh JM, Ahn BC, Wirth LJ, Shin CH, Kim JI, Park YJ. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest. 2021;131:e144847.","journal-title":"J Clin Invest."},{"key":"13271_CR8","doi-asserted-by":"crossref","unstructured":"I. Carretero-Barrio, A. Sant\u00f3n, T. Caniego Casas, E. L\u00f3pez Miranda, M.E. Reguero-Callejas, B. P\u00e9rez-Mies, A. Benito, J. Palacios, Cytological and molecular characterization of secretory breast carcinoma. Diagn Cytopathol. 2022;50:E174-e180.","DOI":"10.1002\/dc.24945"},{"key":"13271_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-019-05506-3","volume":"179","author":"K Kyker-Snowman","year":"2020","unstructured":"Kyker-Snowman K, Hughes RM, Yankaskas CL, Cravero K, Karthikeyan S, Button B, Waters I, Rosen DM, Dennison L, Hunter N, Donaldson J, Christenson ES, Konstantopoulos K, Hurley PJ, Croessmann S, Park BH. TrkA overexpression in nontumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Res Treat. 2020;179:631\u201342.","journal-title":"Breast Cancer Res Treat"},{"key":"13271_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","volume":"5","author":"A Vaishnavi","year":"2015","unstructured":"Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5:25\u201334.","journal-title":"Cancer Discov"},{"key":"13271_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","volume":"5","author":"CB Westphalen","year":"2021","unstructured":"Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, Jin DX, Newberg JY, Fabrizio D, Veronese L, Thomas M, de Braud F. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5:69.","journal-title":"NPJ Precis Oncol"},{"key":"13271_CR12","first-page":"545","volume":"13","author":"S Kummar","year":"2018","unstructured":"Kummar S, Lassen UN, Inhibition TRK. A New Tumor-Agnostic Treatment Strategy, Target. Oncol. 2018;13:545\u201356.","journal-title":"Oncol"},{"key":"13271_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186:631\u201343.","journal-title":"Eur J Endocrinol"},{"key":"13271_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:271\u201382.","journal-title":"Lancet Oncol"},{"issue":"Suppl 8","key":"13271_CR15","doi-asserted-by":"publisher","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","volume":"30","author":"A Drilon","year":"2019","unstructured":"Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30(Suppl 8):viii23\u201330.","journal-title":"Ann Oncol"},{"key":"13271_CR16","doi-asserted-by":"crossref","unstructured":"AM Lange, HW Lo. Inhibiting TRK Proteins in Clinical Cancer Therapy. Cancers (Basel). 20218;10:105.","DOI":"10.3390\/cancers10040105"},{"key":"13271_CR17","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/cncr.29887","volume":"122","author":"ML Prasad","year":"2016","unstructured":"Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016;122:1097\u2013107.","journal-title":"Cancer"},{"key":"13271_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.21.01861","volume":"40","author":"AT Franco","year":"2022","unstructured":"Franco AT, Ricarte-Filho JC, Isaza A, Jones Z, Jain N, Mostoufi-Moab S, Surrey L, Laetsch TW, Li MM, DeHart JC, Reichenberger E, Taylor D, Kazahaya K, Adzick NS, Bauer AJ. Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers. J Clin Oncol. 2022;40:1081\u201390.","journal-title":"J Clin Oncol"},{"key":"13271_CR19","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/PAS.0000000000001929","volume":"46","author":"DC Costigan","year":"2022","unstructured":"Costigan DC, Nucci MR, Dickson BC, Chang MC, Song S, Sholl LM, Hornick JL, Fletcher CDM, Kolin DL. NTRK -Rearranged Uterine Sarcomas: Clinicopathologic Features of 15 Cases, Literature Review, and Risk Stratification. Am J Surg Pathol. 2022;46:1415\u201329.","journal-title":"Am J Surg Pathol"},{"key":"13271_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/PAS.0000000000001377","volume":"44","author":"J Lasota","year":"2020","unstructured":"Lasota J, Ch\u0142opek M, Lamoureux J, Christiansen J, Kowalik A, Was\u0105g B, Felisiak-Go\u0142\u0105bek A, Agaimy A, Biernat W, Canzonieri V, Centonze G, Chmielik E, Daum O, Dubov\u00e1 M, Dziuba I, Goertz S, G\u00f3\u017ad\u017a S, Guttmejer-Nasierowska A, Haglund C, Ha\u0142o\u0144 A, Hartmann A, Inaguma S, I\u017cycka-\u015awieszewska E, Kaczorowski M, Kita P, Ko\u0142os M, Kopczy\u0144ski J, Michal M, Milione M, Oko\u0144 K, P\u0119ksa R, Pyzlak M, Ristim\u00e4ki A, Ry\u015b J, Szostak B, Szpor J, Szumi\u0142o J, Teresi\u0144ski L, Waloszczyk P, Wejman J, Weso\u0142owski W, Miettinen M. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature. Am J Surg Pathol. 2020;44:162\u201373.","journal-title":"Am J Surg Pathol"},{"key":"13271_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/blood-2018-05-849554","volume":"132","author":"KG Roberts","year":"2018","unstructured":"Roberts KG, Janke LJ, Zhao Y, Seth A, Ma J, Finkelstein D, Smith S, Ebata K, Tuch BB, Hunger SP, Mullighan CG. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition. Blood. 2018;132:861\u20135.","journal-title":"Blood"},{"key":"13271_CR22","doi-asserted-by":"publisher","first-page":"15987","DOI":"10.1038\/ncomms15987","volume":"8","author":"PJ Cook","year":"2017","unstructured":"Cook PJ, Thomas R, Kannan R, de Leon ES, Drilon A, Rosenblum MK, Scaltriti M, Benezra R, Ventura A. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. Nat Commun. 2017;8:15987.","journal-title":"Nat Commun"},{"key":"13271_CR23","doi-asserted-by":"publisher","first-page":"17491","DOI":"10.1074\/jbc.M210529200","volume":"278","author":"M Mongiat","year":"2003","unstructured":"Mongiat M, Fu J, Oldershaw R, Greenhalgh R, Gown AM, Iozzo RV. Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem. 2003;278:17491\u20139.","journal-title":"J Biol Chem"},{"key":"13271_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jss.2007.10.014","volume":"149","author":"G Lal","year":"2008","unstructured":"Lal G, Padmanabha L, Nicholson R, Smith BJ, Zhang L, Howe JR, Robinson RA, O\u2019Dorisio MS. ECM1 expression in thyroid tumors\u2013a comparison of real-time RT-PCR and IHC. J Surg Res. 2008;149:62\u20138.","journal-title":"J Surg Res"},{"key":"13271_CR25","first-page":"2983","volume":"11","author":"W Huang","year":"2019","unstructured":"Huang W, Huang Y, Gu J, Zhang J, Yang J, Liu S, Xie C, Fan Y, Wang H. miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression. Am J Transl Res. 2019;11:2983\u201394.","journal-title":"Am J Transl Res"},{"key":"13271_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12957-016-0952-z","volume":"14","author":"H Chen","year":"2016","unstructured":"Chen H, Jia W, Li J. ECM1 promotes migration and invasion of hepatocellular carcinoma by inducing epithelial\u2013mesenchymal transition. World J Surg Oncol. 2016;14:195.","journal-title":"World J Surg Oncol"},{"key":"13271_CR27","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1038\/onc.2015.54","volume":"34","author":"KM Lee","year":"2015","unstructured":"Lee KM, Nam K, Oh S, Lim J, Kim RK, Shim D, Choi JH, Lee SJ, Yu JH, Lee JW, Ahn SH, Shin I. ECM1 regulates tumor metastasis and CSC-like property through stabilization of \u03b2-catenin. Oncogene. 2015;34:6055\u201365.","journal-title":"Oncogene"},{"key":"13271_CR28","doi-asserted-by":"publisher","first-page":"889159","DOI":"10.3389\/fonc.2022.889159","volume":"12","author":"S Long","year":"2022","unstructured":"Long S, Wang J, Weng F, Xiang D, Sun G. Extracellular Matrix Protein 1 Regulates Colorectal Cancer Cell Proliferative, Migratory, Invasive and Epithelial-Mesenchymal Transition Activities Through the PI3K\/AKT\/GSK3\u03b2\/Snail Signalling Axis. Front Oncol. 2022;12:889159.","journal-title":"Front Oncol"},{"key":"13271_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10585-016-9827-5","volume":"34","author":"P G\u00f3mez-Contreras","year":"2017","unstructured":"G\u00f3mez-Contreras P, Ramiro-D\u00edaz JM, Sierra A, Stipp C, Domann FE, Weigel RJ, Lal G. Extracellular matrix 1 (ECM1) regulates the actin cytoskeletal architecture of aggressive breast cancer cells in part via S100A4 and Rho-family GTPases. Clin Exp Metastasis. 2017;34:37\u201349.","journal-title":"Clin Exp Metastasis"},{"key":"13271_CR30","doi-asserted-by":"publisher","first-page":"673873","DOI":"10.3389\/fcell.2021.673873","volume":"9","author":"T Zhang","year":"2021","unstructured":"Zhang T, Chen S, Peng Y, Wang C, Cheng X, Zhao R, Liu K. NOVA1-Mediated SORBS2 Isoform Promotes Colorectal Cancer Migration by Activating the Notch Pathway. Front Cell Dev Biol. 2021;9:673873.","journal-title":"Front Cell Dev Biol"},{"key":"13271_CR31","doi-asserted-by":"publisher","first-page":"e12348","DOI":"10.1111\/cpr.12348","volume":"50","author":"Y Xin","year":"2017","unstructured":"Xin Y, Li Z, Zheng H, Ho J, Chan MTV, Wu WKK. Neuro-oncological ventral antigen 1 (NOVA1): Implications in neurological diseases and cancers. Cell Prolif. 2017;50:e12348.","journal-title":"Cell Prolif."},{"key":"13271_CR32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-022-10164-8","volume":"22","author":"L Qu","year":"2022","unstructured":"Qu L, Tian Y, Wang F, Li Z. NOVA1 promotes NSCLC proliferation and invasion by activating Wnt\/\u03b2-catenin signalling. BMC Cancer. 2022;22:1091.","journal-title":"BMC Cancer"},{"key":"13271_CR33","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"13271_CR34","doi-asserted-by":"publisher","first-page":"e109124","DOI":"10.1371\/journal.pone.0109124","volume":"9","author":"F Zhi","year":"2014","unstructured":"Zhi F, Wang Q, Deng D, Shao N, Wang R, Xue L, Wang S, Xia X, Yang Y. MiR-181b-5p downregulates NOVA1 to suppress proliferation, migration and invasion and promote apoptosis in astrocytoma. PLoS ONE. 2014;9:e109124.","journal-title":"PLoS ONE"},{"key":"13271_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340.","journal-title":"Lancet Oncol"},{"key":"13271_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","volume":"79","author":"LJ Scott","year":"2019","unstructured":"Scott LJ. Larotrectinib: First Global Approval. Drugs. 2019;79:201\u20136.","journal-title":"Drugs"},{"key":"13271_CR37","doi-asserted-by":"crossref","unstructured":"Entrectinib Effective across NTRK Fusion-Positive Cancers. Cancer Discov. 20219;9:Of4.","DOI":"10.1158\/2159-8290.CD-NB2018-156"},{"key":"13271_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/ijms23010395","volume":"23","author":"SH Sohn","year":"2021","unstructured":"Sohn SH, Sul HJ, Kim BJ, Kim HS, Zang DY. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression. Int J Mol Sci. 2021;23:395.","journal-title":"Int J Mol Sci."},{"key":"13271_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/00000478-200007000-00005","volume":"24","author":"JM Bourgeois","year":"2000","unstructured":"Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24:937\u201346.","journal-title":"Am J Surg Pathol"},{"key":"13271_CR40","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1309\/3H24-E7T7-V37G-AKKQ","volume":"115","author":"WQ Sheng","year":"2001","unstructured":"Sheng WQ, Hisaoka M, Okamoto S, Tanaka A, Meis-Kindblom JM, Kindblom LG, Ishida T, Nojima T, Hashimoto H. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol. 2001;115:348\u201355.","journal-title":"Am J Clin Pathol"},{"key":"13271_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","volume":"21","author":"SJ Hsiao","year":"2019","unstructured":"Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. J Mol Diagn. 2019;21:553\u201371.","journal-title":"J Mol Diagn"},{"key":"13271_CR42","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41379-020-0574-4","volume":"33","author":"YH Chu","year":"2020","unstructured":"Chu YH, Dias-Santagata D, Farahani AA, Boyraz B, Faquin WC, Nos\u00e9 V, Sadow PM. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Mod Pathol. 2020;33:2186\u201397.","journal-title":"Mod Pathol"},{"key":"13271_CR43","doi-asserted-by":"publisher","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","volume":"30","author":"A Amatu","year":"2029","unstructured":"Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2029;30:viii5\u201315.","journal-title":"Ann Oncol"},{"key":"13271_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/01.sla.0000179623.87329.6b","volume":"242","author":"E Kebebew","year":"2005","unstructured":"Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg. 2005;242:353\u201361 discussion 361\u2013353.","journal-title":"Ann Surg."},{"key":"13271_CR45","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1002\/cncr.21922","volume":"106","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Peng M, Reiff E, McMillan A. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer. 2006;106:2592\u20137.","journal-title":"Cancer"},{"key":"13271_CR46","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s10120-016-0623-3","volume":"20","author":"EK Kim","year":"2017","unstructured":"Kim EK, Yoon SO, Jung WY, Lee H, Kang Y, Jang YJ, Hong SW, Choi SH, Yang WI. Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation. Gastric Cancer. 2017;20:438\u201347.","journal-title":"Gastric Cancer"},{"key":"13271_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.suronc.2019.09.009","volume":"31","author":"YG Hong","year":"2019","unstructured":"Hong YG, Xu GS, Yu GY, Zhou JD, Liu QZ, Ni JS, Yan HL, Zhang W, Hao LQ. The RNA binding protein neuro-oncological ventral antigen 1 (NOVA1) regulates IL-6 mRNA stability to enhance JAK2-STAT3 signalling in CRC. Surg Oncol. 2019;31:67\u201374.","journal-title":"Surg Oncol"},{"key":"13271_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cncr.25369","volume":"117","author":"MR Vriens","year":"2011","unstructured":"Vriens MR, Moses W, Weng J, Peng M, Griffin A, Bleyer A, Pollock BH, Indelicato DJ, Hwang J, Kebebew E. Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer. 2011;117:259\u201367.","journal-title":"Cancer"},{"key":"13271_CR49","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.3390\/ijms21134629","volume":"21","author":"S Szpak-Ulczok","year":"2020","unstructured":"Szpak-Ulczok S, Pfeifer A, Rusinek D, Oczko-Wojciechowska M, Kowalska M, Tyszkiewicz T, Cieslicka M, Handkiewicz-Junak D, Fujarewicz K, Lange D, Chmielik E, Zembala-Nozynska E, Student S, Kotecka-Blicharz A, Kluczewska-Galka A, Jarzab B, Czarniecka A, Jarzab M, Krajewska J. Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma-Do They Exist? Int J Mol Sci. 2020;21:4629.","journal-title":"Int J Mol Sci."},{"key":"13271_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41389-023-00454-6","volume":"12","author":"F Vanoli","year":"2023","unstructured":"Vanoli F, Herviou L, Tsuda Y, Sung P, Xie Z, Fishinevich E, Min SS, Mallen W, de Wardin HT, Zhang Y, Jasin M, Antonescu CR. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy. Oncogenesis. 2023;12:8.","journal-title":"Oncogenesis"},{"key":"13271_CR51","first-page":"5","volume":"4","author":"C Racca","year":"2010","unstructured":"Racca C, Gardiol A, Eom T, Ule J, Triller A, Darnell RB. The Neuronal Splicing Factor Nova Co-Localizes with Target RNAs in the Dendrite. Front Neural Circuits. 2010;4:5.","journal-title":"Front Neural Circuits"},{"key":"13271_CR52","doi-asserted-by":"publisher","first-page":"194413","DOI":"10.1016\/j.bbagrm.2019.194413","volume":"1862","author":"V Gumina","year":"2019","unstructured":"Gumina V, Colombrita C, Fallini C, Bossolasco P, Maraschi AM, Landers JE, Silani V, Ratti A. TDP-43 and NOVA-1 RNA-binding proteins as competitive splicing regulators of the schizophrenia-associated TNIK gene. Biochim Biophys Acta Gene Regul Mech. 2019;1862:194413.","journal-title":"Biochim Biophys Acta Gene Regul Mech"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13271-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T12:02:57Z","timestamp":1733400177000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13271-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13271"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13271-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved, and the need for informed consent was waived by the Medical Ethics Committee of Xiangya Hospital, Central South University (ratification number: 202307139).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"As a retrospective analysis of patient medical records, the patient medical record information utilized in this study has undergone review and received approval from the Medical Ethics Committee of Xiangya Hospital of Central South University for exemption from the requirement of informed consent. Given that this manuscript does not contain any images that divulge patients' personal information, the statement regarding patients' consent for release is not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1502"}}